相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
Jeffrey A. Lieberman et al.
BIOLOGICAL PSYCHIATRY (2016)
ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers
Robert E. Davis et al.
PSYCHOPHARMACOLOGY (2015)
A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
John M. Kane et al.
SCHIZOPHRENIA RESEARCH (2015)
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
Christoph U. Correll et al.
WORLD PSYCHIATRY (2015)
Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study
Christoph U. Correll et al.
WORLD PSYCHIATRY (2015)
Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
Gretchen L. Snyder et al.
PSYCHOPHARMACOLOGY (2015)
Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia
Maren Carbon et al.
CNS SPECTRUMS (2014)
Emerging drugs for schizophrenia: an update
Luisa-Sophie Koester et al.
EXPERT OPINION ON EMERGING DRUGS (2014)
Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders
Peng Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Reviewing the ketamine model for schizophrenia
Joel Frohlich et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
Antipsychotic-Induced Metabolic and Cardiovascular Side Effects in Schizophrenia: A Novel Mechanistic Hypothesis
Giulio Scigliano et al.
CNS DRUGS (2013)
5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders
Tiago A. Mestre et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Stefan Leucht et al.
LANCET (2013)
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia
Stephen R. Marder et al.
SCHIZOPHRENIA RESEARCH (2013)
Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo
Virginia L. Stauffer et al.
SCHIZOPHRENIA RESEARCH (2013)
Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies
John M. Kane et al.
WORLD PSYCHIATRY (2013)
Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?
Larry Alphs et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2012)
Exploratory Analyses of Efficacy Data From Schizophrenia Trials in Support of New Drug Applications Submitted to the US Food and Drug Administration
Ni A. Khin et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010
Joshua A. Salomon et al.
LANCET (2012)
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Christopher J. L. Murray et al.
LANCET (2012)
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Theo Vos et al.
LANCET (2012)
A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Stephen S. Lim et al.
LANCET (2012)
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
Marc De Hert et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study
Herbert Y. Meltzer et al.
AMERICAN JOURNAL OF PSYCHIATRY (2011)
Serotonin 2A receptor antagonists for treatment of schizophrenia
Bjorn H. Ebdrup et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Mid-Term and Long-Term Efficacy and Effectiveness of Antipsychotic Medications for Schizophrenia: A Data-Driven, Personalized Clinical Approach
Ira D. Glick et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Antipsychotic drugs and obesity
Christoph U. Correll et al.
TRENDS IN MOLECULAR MEDICINE (2011)
Increased Serotonin 2A Receptor Availability in the Orbitofrontal Cortex of Physically Aggressive Personality Disordered Patients
Daniel R. Rosell et al.
BIOLOGICAL PSYCHIATRY (2010)
From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics
C. U. Correll
EUROPEAN PSYCHIATRY (2010)
Past and Present Progress in the Pharmacologic Treatment of Schizophrenia
John M. Kane et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
Christoph U. Correll et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Stefan Leucht et al.
LANCET (2009)
The Dopamine Hypothesis of Schizophrenia: Version III - The Final Common Pathway
Oliver D. Howes et al.
SCHIZOPHRENIA BULLETIN (2009)
Balancing efficacy and safety in treatment with antipsychotics
Christoph U. Correll
CNS SPECTRUMS (2007)
Modern antipsychotic drugs: a critical overview
DM Gardner et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2005)
Clozapine potentiation of N-methyl-D-aspartate receptor currents in the nucleus accumbens:: Role of NR2B and protein kinase A/Src kinases
M Wittmann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
World Federation of Societies of Biological Psychiatry (WFSBP) - Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia
P Falkai et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2005)
Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders
GJ Marek et al.
NEUROPSYCHOPHARMACOLOGY (2003)
Assessing positive and negative symptoms in outpatients with schizophrenia and mood disorders
DM Purnine et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2000)
分享论文
